Compare Alcon AG (ALC) vs Ambarella Inc (AMBA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alcon AG vs Ambarella Inc — how do they compare? Alcon AG trades at $73.17 (market cap $35.19B), while Ambarella Inc trades at $83.72 (market cap $3.60B). The key difference: Alcon AG is far larger — about 9.8× Ambarella Inc's market cap, and Alcon AG pays a 0.49% dividend while Ambarella Inc pays none. Which is the better fit depends on your goals.
| ALC | AMBA | |
|---|---|---|
Market Cap | $35.19B | $3.60B |
Sector | Health | Technology |
52-Week High | $90.12 | $95.51 |
52-Week Low | $62.02 | $48.65 |
Enterprise Value | $39.03B | $3.33B |
Dividend Yield | 0.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $71.81, up 3.26% today, with a bullish technical signal supported by moving averages and ADX indicators. The company reported Q2 2026 EPS of $0.84, beating estimates, and raised its profit guidance on August 11, 2026, citing strong product launches. Revenue grew to $10.4B in 2025, though net income margin dipped to 9.42%. Valuation ratios include a P/E of 43 and P/S of 3.34, reflecting premium pricing.
Outlook is positive with analyst consensus at 54% buy ratings and a 27.8% upside target, but risks include margin pressure and high debt. The stock offers growth potential from innovation but faces competitive and macroeconomic headwinds.
Ambarella (AMBA) trades at $86.78, up 3.57% with strong technical momentum. The stock shows bullish moving average signals despite negative profitability metrics. Recent news highlights NXP's potential acquisition interest and the company's strategic pivot to edge AI chips, driving analyst optimism. Q2 2026 earnings are expected at $0.171 per share, following three consecutive quarterly beats. Revenue growth is projected to accelerate from $285M in 2025 to $405M in 2026.
Outlook remains positive with 58% analyst buy ratings and $108.67 price target, but risks include persistent net losses, high valuation multiples, and competitive pressure in semiconductor space. The edge AI transition offers growth potential, yet execution risks and insider selling warrant caution for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About Ambarella Inc
Ambarella is a semiconductor company specializing in low-power video compression and computer vision processors. Its chips power AI cameras for security, automotive safety, and robotics applications.
Read more on AMBA →
